Johnson & Johnson was honored as one of Fast Company’s top ten most innovative biotech companies. Johnson & Johnson was recognized for its incubation of medical startups. Learn more about the ranking on Fast Company’s website. Check out JLABS to learn more about how we support startups.
Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer.
Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.
Inflammation is the body’s natural response to injury or infection. But when it lingers, inflammation can lead to immune-mediated inflammatory diseases. Learn how Johnson & Johnson is innovating to help bring relief to those living with chronic inflammatory conditions.
